DESyne X2 Post Market Follow-up Study

NCT ID: NCT04375085

Last Updated: 2023-10-25

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 49 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-01
• Study Completion Date: 2021-12-28

Brief Summary

A single-arm post-market clinical follow-up study to confirm that the DESyne X2 delivery system performs similarly to the DESyne delivery system.

Detailed Description

A single-arm post-market follow up study (PMCF) comparing the DESyne X2 PMCF data to the historic DESyne acute performance data to confirm the performance of the DESyne X2 Novolimus Eluting Coronary Stent System with regards to the residual risks of lesion access and acute device implantation through visually-assessed angiographic endpoints and physician feedback.

Conditions

Coronary Artery Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

DESyne X2 Novolimus Eluting Coronary Stent System

Group Type: OTHER

Percutaneous Coronary Intervention

Intervention Type: DEVICE

Percutaneous Coronary Intervention

Interventions

Percutaneous Coronary Intervention

Percutaneous Coronary Intervention

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. The patient must be ≥ 18 years of age.

2. The patient must have stable angina pectoris as defined by the Canadian Cardiovascular Society Classification, documented silent ischemia, acute coronary syndrome, or a positive functional study requiring treatment

3. The patient is considered a candidate for coronary stent implantation and has a planned intervention of up to two lesions located in separate major epicardial territories. Each lesion/vessel must meet the following criteria:

1. De novo lesion

2. The target lesion reference site must be visually estimated to be ≥ 2.5 mm and ≤ 4.0 mm in diameter

3. The target vessel must be a major coronary artery or major branch with a visually estimated stenosis of ≥ 50% and < 100%.

4. The visually estimated target lesion length must be ≤ 34 mm

5. ≥ TIMI 1 coronary flow

Exclusion Criteria

1. The patient has a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, prasugrel or ticagrelor, heparin/bivalirudin, mTOR inhibitor class drugs, cobalt chromium alloy, methacrylate or polylactide polymer, or sensitivity to contrast which cannot be adequately premedicated

2. Women of childbearing potential who have not undergone surgical sterilization or are not post-menopausal (defined as amenorrheic for at least one year) as well as women who are pregnant or nursing

3. Previous placement of a stent within 10 mm distal to the target lesion

4. Previous placement of a stent proximal to the target lesion

5. Total occlusion or < TIMI 1 coronary flow in the target vessel

6. The proximal target vessel or target lesion is severely calcified by visual assessment

7. Aorto-ostial location, unprotected left main lesion location, or a lesion within 5 mm of the origin of the left anterior descending or left circumflex

8. Lesion involvement of a significant side branch (branch diameter > 2 mm) that would be covered by stenting

9. High probability that treatment other than PTCA or stenting will be required for treatment of the same lesion

10. The target lesion, or the target vessel proximal to the target lesion, contains thrombus

11. The patient has suffered a myocardial infarction within the past 72 hours and the CK or CK-MB has not returned to normal at the time of the index procedure

12. The patient is a recipient of a heart transplant

13. The patient has extensive peripheral vascular disease that precludes safe sheath insertion or extreme anti-coagulation

14. The patient is currently participating in another investigational device or drug study that has not completed the primary follow-up phase

15. Patients who are unable or unwilling to cooperate with study procedures

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Elixir Medical Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Kwong Wah Hospital

Hong Kong, Kowloon, China

Queen Elizabeth Hospital

Hong Kong, Kowloon, China

Tseung Kwan O Hospital

Hong Kong, , China

Countries

China

Provided Documents

Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form

View Document

Other Identifiers

ELX-CL-1705

Identifier Type: -

Identifier Source: org_study_id